Datasheet

CD80 Antibody [11D1]
CATALOG NUMBER: RF16044

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human
TESTED APPLICATIONS:ELISA, Flow, ICC, IF, IHC-P
APPLICATIONS:CD80 antibody can be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 5 μg/mL. Flow cytometry at 10 μg/ml.

Antibody validated: Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1340 - Human Stomach Carcinoma Tissue Lysate
 2) Cat. No. 1315 - Human Tonsil Tissue
PREDICTED MOLECULAR WEIGHT:Predicted: 32 kDa

Observed: 50 kDa
IMMUNOGEN:CD80 antibody was raised against the extracellular domain of human CD80.
HOST SPECIES:Mouse

Properties

PURIFICATION:CD80 Antibody is supplied as protein A purified IgG1.
PHYSICAL STATE:Liquid
BUFFER:CD80 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CD80 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Monoclonal
ISOTYPE:IgG1
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:CD80 Antibody: CD80 molecule, B7, BB1, B7-1, B7.1, LAB7, CD28LG, CD28LG1
ACCESSION NO.:NP_005182
PROTEIN GI NO.:4885123
OFFICIAL SYMBOL:CD80
GENE ID:941

Background

BACKGROUND:CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).
REFERENCES: 1) Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann NY Acad Sci 1997; 815:392-400.
2) Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7:76902-19.

For Research Use Only